Loading...
menu
Search
Features
Markets
News
Resources
Pricing
Home
ETF
LGND
LGND
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
Latest LGND ETF News Today | Earnings, Events & Price Alerts
LGND News
Ligand Pharmaceuticals Reports Strong Q4 2025 Earnings and Growth Outlook
5d ago
seekingalpha
Ligand Pharmaceuticals Reports Strong 2025 Financial Performance with 48% Royalty Revenue Growth
6d ago
Newsfilter
Ligand Pharmaceuticals Releases 2026 Financial Guidance
6d ago
seekingalpha
Ligand Pharmaceuticals Set to Announce Q4 Earnings on February 26
Feb 25 2026
seekingalpha
S&P 500 and Dow Reverse Gains as Nasdaq Narrows Upturn
Jan 08 2026
Yahoo Finance
S&P 500 and Dow Retreat from Highs, Eli Lilly and Google Flash Buy Signals
Jan 08 2026
Yahoo Finance
A Biotech Investment Option for Cautious Investors in a Volatile Sector
Dec 09 2025
CNBC
Ligand Pharmaceuticals Introduces 2026 Revenue Guidance of $245M to $285M
Dec 09 2025
Newsfilter
Orchestra BioMed Announces Financial Results for Q3 2025 and Shares Recent Business Developments
Nov 10 2025
Globenewswire
Pelthos Therapeutics Purchases Xepi® (ozenoxacin) Cream, 1%, and Reveals $18 Million Private Convertible Notes Funding
Nov 07 2025
Newsfilter
EXCLUSIVE: Pelthos Acquires Antimicrobial Drug Rights and Raises $18 Million for Commercial Launch Support
Nov 07 2025
Benzinga
HC Wainwright & Co. Reaffirms Buy Rating for Ligand Pharmaceuticals, Increases Price Target to $231
Nov 06 2025
Benzinga
MSTZ and AFSC Experience Significant ETF Withdrawals
Oct 17 2025
NASDAQ.COM
Ligand Scheduled to Hold Investor Day on December 9, 2025
Oct 16 2025
Newsfilter
SQ Innovation, a Ligand Partner, Secures FDA Approval for Lasix® ONYU, a Home Treatment for Edema in Heart Failure Patients
Oct 09 2025
Newsfilter
Ligand Pharmaceuticals Achieves Analyst Price Target
Oct 09 2025
NASDAQ.COM
Show More News
